0
0
JOHANNESBURG, July 13 – South Africa’s ambitious HIV vaccine research program came to an abrupt halt this week after the United States government withdrew $46 million in funding, just days before clinical trials were set to begin. The move, part of a broader rollback of US foreign aid under former President Donald Trump’s “America First” policy, has devastated scientists and threatens to unravel years of hard-won progress in the global fight against HIV.
The BRILLIANT program, a cornerstone of HIV research in the world’s hardest-hit region, now faces possible collapse. South Africa, which has been receiving around $400 million annually from the US through USAID and the HIV-focused PEPFAR initiative, has been hit especially hard by the cuts. The withdrawal has led to immediate layoffs of hundreds of researchers and health workers, the freezing of equipment purchases, and the suspension of ongoing work at major institutions such as the University of the Witwatersrand.
Professor Glenda Gray, who leads the BRILLIANT program, warned that the funding cut imperils not only local jobs and research but also international scientific collaboration. “Without South Africa in these programmes, the world is much poorer,” Gray said, highlighting the country’s pivotal role in clinical trials for both HIV prevention and COVID-19 vaccines.
The South African government estimates a loss of $107 million in US research aid over the next five years, affecting projects targeting both HIV and tuberculosis. At least 8,000 health workers and thousands of field data collectors have already been let go, severely disrupting HIV care and prevention in rural communities where the virus remains rampant.
The impact extends beyond South Africa’s borders. UNAIDS executive director Winnie Byanyima acknowledged that while some African nations are increasing domestic funding, these efforts are unlikely to compensate for the scale of lost American support. “What they are putting down will not be funding in the same way that the American resources were funding,” Byanyima said.
Experts now fear a sharp rise in HIV infections and a reversal of decades of progress. The United Nations has warned that unless new funding sources are found, the cessation of US support could lead to millions more HIV infections and deaths by 2029, undermining global efforts to end AIDS as a public health threat.
As the BRILLIANT program scrambles for alternative financing, the future of HIV vaccine research in South Africa—and the world—hangs in the balance.
Disclaimer: This article is based on current information as of July 14, 2025. The situation regarding US foreign aid and its impact on global health research is evolving. For the latest updates, consult official sources and health agencies.
